For GLP/Ehmt1, the gene level was higher in metastatic disease compared with patients with no evidence of disease (Figure 4A,B) In addition, patients bearing ES tumors with higher GLP/Ehmt1 levels showed a significant reduction in OS compared with patients with lower GLP/Ehmt1 levels (Figure 4C). This evidence concerns the gene EHMT1 and Ewing sarcoma.